

Clinical Trial Protocol

Iranian Registry of Clinical Trials

18 Sep 2026

Bioequivalence study of Everolimus 0.75mg manufactured by Alborz Zagros company versus originator brand in healthy volunteers in fasting condition

Protocol summary

Study aim

Bioequivalence Study of Everolimus 0.75 mg manufactured by Alborz Zagros company versus originator brand (Certican) manufactured by Novartis company

Design

Bioequivalence study, crossover, single-blinded, 24 healthy volunteers. Simple randomization was used for randomization

Settings and conduct

The study is a single-blinded, cross-over and fasting, and on two series of healthy volunteers. The study will be done in two periods (72h). The interval between these two periods is 2 weeks. In the first round of the study, the candidates divide into two groups and the first group receives a test tablet and the second group receives a brand tablet. Blood samples are collected immediately before and after drug administration by volunteers. Then, drug extraction is done and samples are ready for analysis.

Participants/Inclusion and exclusion criteria

Inclusion Criteria: General Health (Liver, Heart, and Kidney), Body Mass Index (18-28), Informed consent, Age (18-55 years old) Exclusion criteria: Smoking, History of cardiovascular disease, History of liver and kidney disease, Alcohol and drug addiction, History of allergy to Everolimus

Intervention groups

Intervention group 1: Certican 0.75mg tablet as a reference Intervention group 2: Everolimus 0.75mg manufactured by Alborz zagros as a test

Main outcome variables

Maximum drug concentration, Time to reach maximum drug concentration, Half-life of drug

General information

Reason for update

Changing the name of laboratory for sampling and analysis

Acronym

IRCT registration information

IRCT registration number: **IRCT20200623047902N12**

Registration date: **2022-01-01, 1400/10/11**

Registration timing: **registered_while_recruiting**

Last update: **2025-06-29, 1404/04/08**

Update count: **1**

Registration date

2022-01-01, 1400/10/11

Registrant information

Name

Elham Ghasemian

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 6696 5196

Email address

ghasemian@zistdaru.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-12-22, 1400/10/01

Expected recruitment end date

2022-03-20, 1400/12/29

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Bioequivalence study of Everolimus 0.75mg manufactured by Alborz Zagros company versus originator brand in healthy volunteers in fasting condition

Public title

Bioequivalence study of Everolimus 0.75mg tablet

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

General Health (Liver, Heart, and Kidney) Body Mass Index (18-28) Informed consent Age (18-55 years old)

Exclusion criteria:

Smoking History of cardiovascular disease History of liver and kidney disease Alcohol and drug addiction History of allergy to Everolimus

Age

From **18 years** old to **55 years** old

Gender

Both

Phase

Bioequivalence

Groups that have been masked

- Participant

Sample size

Target sample size: **24**

More than 1 sample in each individual

Number of samples in each individual: **15**

Blood sample

Randomization (investigator's opinion)

Randomized

Randomization description

People in the mentioned age group are invited to participate through the advertisement. People are then checked for health and healthy volunteers are identified. Each candidate is assigned a number from 1 to 24. The numbers are written on a plastic ball and poured into a container and mixed. The balls are then removed randomly from the container. The first 12 no.s are considered as (first sequence: Alborz Zagros's medicine) and the second 12 no.s are considered as (second sequence: originator brand recipient). The volunteers don't have any information about taking the test drug or brand drug

Blinding (investigator's opinion)

Single blinded

Blinding description

This study is a single-blinded clinical trial (volunteers). Alborz Zagros's Everolimus and Originator brand's tablets are removed from their packaging by the executor and placed in similar and coded cans. Volunteers will not be informed about receiving the brand or test dosage form

Placebo

Not used

Assignment

Crossover

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Research Ethics Committees of Tabriz University of Medical Sciences

Street address

International Relations Office, No 2 Central Building, Tabriz University of Medical Sciences, Golgasht Street,

City

Tabriz

Province

East Azarbaijan

Postal code

5165665931

Approval date

2021-11-29, 1400/09/08

Ethics committee reference number

IR.TBZMED.REC.1400.829

Health conditions studied**1****Description of health condition studied**

This study is performed on healthy volunteers.

ICD-10 code**ICD-10 code description****Primary outcomes****1****Description**

Drug plasma concentration

Timepoint

0; 0.5; 1; 1.5;2; 2.5; 3; 4; 6; 8; 10; 12; 24; 48; 72h after drug administration

Method of measurement

Liquid Chromatography -MASS-MASS (LC-MASS/MASS)

Secondary outcomes**1****Description**

Pharmacokinetic parameters

Timepoint

After intervention

Method of measurement

Theoretical and pahrmacokinetic equations

Intervention groups

1

Description

Intervention group: single dose, 2 oral tablet 0.75mg (Certican) manufactured by Novartis, as a reference product

Category

Treatment - Drugs

2

Description

Intervention group: Single dose, 2 oral tablet 0.75mg manufactured by Alborz Zagros company as test product

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Dr. Shokri laboratory

Full name of responsible person

Javad Shokri

Street address

No.48, Ferdos Street

City

Tabriz

Province

East Azarbaijan

Postal code

5167874434

Phone

+98 41 3384 2724

Email

Shokri.j@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Alborz Zagros company

Full name of responsible person

Amir Hossein Zolfaghari

Street address

No.58, 8th St. Kooye Nasr (Gisha St.)

City

Tehran

Province

Tehran

Postal code

1446863914

Phone

+98 21 4163 7000

Email

A.zolfaghari@alborzzagros.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Alborz Zagros company

Proportion provided by this source

100

Public or private sector

Private

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Industry

Person responsible for general inquiries

Contact

Name of organization / entity

Islamic Azad University

Full name of responsible person

Elham Ghasemian

Position

Visiting professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

No.58, 8th St. Kooye Nasr (Gisha St.)

City

Tehran

Province

Tehran

Postal code

1446863914

Phone

+98 21 4163 7000

Email

Ghasemian_elham@yahoo.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Islamic Azad University

Full name of responsible person

Elham Ghasemian

Position

Visiting professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

No.58, 8th St. Kooye Nasr (Gisha St.)

City

Tehran
Province
Tehran
Postal code
1446863914
Phone
+98 21 4163 7000
Email
Ghasemian_elham@yahoo.com

Person responsible for updating data

Contact

Name of organization / entity
Islamic Azad University
Full name of responsible person
Elham Ghasemian
Position
Visiting professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
No.58, 8th St. Kooye Nasr (Gisha St.)
City
Tehran

Province
Tehran
Postal code
1446863914
Phone
+98 21 4163 7000
Email
ghasemian_elham@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

These data are secure between researchers and related industries.

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available